Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
{{output}}
Antiangiogenic therapy has shown promise in the treatment of patients with hepatocellular carcinoma (HCC). Bevacizumab, sorafenib, and sunitinib showed efficacy in patients with HCC; and sorafenib is approved by the FDA for treatment of this cancer. In practic... ...
